Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has provided an announcement.
Zylox-Tonbridge Medical Technology Co., Ltd. announced amendments to its Articles of Association following the issuance of 13.95 million H Shares under its 2025 Share Incentive Scheme. This has resulted in an increase in the company’s registered capital and total share capital, reflecting a strategic move to enhance shareholder value. The amendments, which are administrative in nature, were approved by the Board and do not require further shareholder approval, indicating streamlined governance and operational efficiency.
The most recent analyst rating on (HK:2190) stock is a Hold with a HK$24.50 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a joint stock company incorporated in China, operating in the medical technology industry. The company focuses on developing and providing medical devices and technologies, with a significant presence in both domestic and foreign markets.
YTD Price Performance: 97.40%
Average Trading Volume: 697,470
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.96B
See more insights into 2190 stock on TipRanks’ Stock Analysis page.